Hype and hope at SynBioBeta 2026

SynBioBeta is the premier annual conference for the synthetic biology industry. I’ve been to many of them over the years, but it had been 4 years since my last one. In the Spring of 2022 we were at the tail end of the ZIRP era, though maybe we didn’t know it yet. Things were buzzing, frothy, exciting: this was the first in-person conference since Covid hit….but we had a feeling that it couldn’t last. There was a willful ignorance in the air. American capital markets run on optimism and we were running as fast as we could.

Zymergen had SPAC’d a year prior at a valuation of $3b, but their CEO was fired in August 2021 and the stock was tanking: within a month they would be sold for parts to Ginkgo. We were still a year out from Amyris’ seemingly inevitable bankruptcy in Summer 2023. Motif Foodworks (raised $345m) would survive for another 15 months before imploding. Later that year layoffs and recaps would accelerate (Perfect Day, Impossible, Geltor, Lanzatech).

2023 was year of hanging on, as companies drew down their fortified balance sheets, but by 2024 runway was running out, and the bloodbath continued. We lost lab grown meat companies (New Age Meats, Sci-Fi Foods, Believer Meats, Meatable, Omeat), materials companies (Vitrolabs, Danimer, Bolt Threads), and a wide array of others (Melonfrost, Huue, Circe, Catalog, to name a few). Those who survived did layoffs, pivots, divestments, and everything possible to live to fight another day.

It felt appropriate to return to SynBioBeta this year to see: have we passed through the trough of disillusionment? Are we bumping along the bottom or have we turned a corner?

There is a strange dichotomy at a conference like SynBioBeta. For those of us deep in the synbio ecosystem, it’s a chance to see old friends from far and wide. The community is filled with optimists. There is joy in running into like-minded builders working to make a better future, those of us who know that biotech will transform the global economy in the coming century. But we must acknowledge that there have been very few successes over the last 5 years. Venture investors are tired, they have not returned capital to their LPs, and the refrain on their lips remains: capital efficiency, focus on products that make money, scale as lean as you can. Real risk capital is almost non-existent.

The entrepreneurs who are still building are truly missionaries. The LARPers have moved on to AI. And indeed, AI was everywhere at SynBioBeta. The AIxBio bubble is growing and this roller coaster is still click-clacking its way up. We’ll probably have another couple of years before it pops.

Of course, these cycles are the natural way of things. The builders in biomanufacturing who are still here have survived another winter, maybe the worst one yet, but we have bought up all the used equipment, hired the best talent, and hoovered up IP at 1% of the cost it took to generate. The last four years were a necessary and inevitable reset. Investors funding companies now, with a more pragmatic mindset (if they can avoid AI hype), stand to do well.

And there are new tailwinds: actual economic and geopolitical demand for what biomanufacturing provides. The thesis has always been about resilience, sustainability, and making the things humanity needs from abundant natural resources. Yes, private capital markets dried up, but we are in a new era of US reindustrialization, at the end of “the end of history”, and in a growing great power competition with China.

I left SynBioBeta 2026 feeling optimistic. The last 4 years have been a brutal reset, but the true builders have stayed focused on what matters. I don’t think we’ll return to the era of SPAC’ing synbio companies, but the seeds for the biotech revolution have been planted in the ashes of the last generation, and many great trees will grow.